What does Neuren Pharmaceuticals specialise in?

The company focuses on treatments for central nervous system disorders.

What is Daybue used for?

Daybue is a therapy for specific rare neurological conditions.

Where is Daybue available?

Daybue is currently available in the US with plans for a European launch.

ASX 200 Healthcare Stock Gains Attention in S&P/ASX Indices

3 min read | August 14, 2025 05:04 PM AEST | By Team Kalkine Media

Google News:

ASX 200 Healthcare Stock Gains Attention in S&P/ASX Indices — Image source: Shutterstock

Daybue Sales Performance in the US Market

The company’s lead therapy, Daybue, is licensed to Acadia (NASDAQ:ACAD) for distribution in the United States. Recent updates indicate steady sales progress in the US, with the treatment maintaining its growth trajectory in addressing its targeted conditions. This growth is attributed to expanded sales initiatives and wider market reach.

European Market Preparations

Neuren Pharmaceuticals has outlined plans for an official European market introduction of Daybue. Ahead of formal approval, a limited number of patients have been receiving the therapy through a named patient supply program. The company views the European rollout as an important step in broadening access to its therapy and enhancing global presence.

Pipeline Expansion with NNZ-2591

Beyond Daybue, the company is advancing NNZ-2591, its second key drug candidate. This therapy is designed for rare neurological disorders and is expected to progress into late-stage clinical development. Recruitment for clinical trials in Phelan McDermid syndrome is anticipated to commence shortly, marking a significant development milestone for the program.

Revenue Streams from Royalties

The agreement with Acadia (NASDAQ:ACAD) for Daybue provides Neuren Pharmaceuticals with a royalty stream, contributing to a stable source of income. This revenue is supplemented by milestone payments related to regulatory approvals and market expansions. Such agreements play a vital role in supporting the company’s research and development objectives.

Position in the S&P/ASX Indices

Inclusion in the S&P/ASX indices highlights the company’s standing in the Australian market. Its activities in biotechnology and healthcare place it among notable names in the sector, with operations that span both domestic and international markets.

Frequently Asked Questions

What does Neuren Pharmaceuticals specialise in?
The company focuses on treatments for central nervous system disorders.
What is Daybue used for?
Daybue is a therapy for specific rare neurological conditions.
Where is Daybue available?
Daybue is currently available in the US with plans for a European launch.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.